MedTrace Logo

4-aminopyridine Treatment for Nerve Injury

NCT03701581 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-12-17

No results posted yet for this study

Summary

To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.

Conditions

Interventions

DRUG

4-Aminopyridine

FDA-approved tablets.

OTHER

Placebo

Placebo will be tooled to look similar to the study drug.

Sponsors & Collaborators

  • John Elfar

    lead OTHER

Principal Investigators

  • Rashid Sayyid, MD · University of Arizona

  • John Elfar, MD · University of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-05
Primary Completion
2027-07-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03701581 on ClinicalTrials.gov